Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHRM 864 > Lecture 13 - Lung Cancer > Flashcards

Lecture 13 - Lung Cancer Flashcards

(50 cards)

Start Studying
1
Q

Lung cancer is the ____ most common

A

2nd
#1 killer
survival rates have greatly improved

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Risk factors

A

tobacco, occupational/environmental exposure to asbestos, heavy metals, radon, polycyclic aromatic hydrocarbons, ionizing radiation, genetic predisposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Etiology

A

chronic exposure of epithelial cells to carcinogens results in chronic inflammation; induces genetic and cytologic changes which eventually lead to carcinogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Etiology - EGFR mutations

A

can predict sensitivity to tyrosine kinase inhibitor therapy
T790M mutations: resistance to therapies (osimertinib is drug for this mutation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Etiology - K-RAS mutations

A

predict resistance to TKIs
in adenocarcinomas, mutations are exclusive to smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Etiology - ALK inhibition

A

less sensitive to EGFR inhibitors and chemo
present in no/light smokers, young age, adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Etiology - ROS-1 mutations

A

encodes a receptor kinase related to ALK
present in never/light smoker, young pts, adenocarcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Etiology - BRAF V600E

A

in current/former smokers
recommended to rest in 1st line metastatic setting for NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Etiology - PD-L1 status

A

recommended to test status in 1st line metastatic setting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Histologic classification

A

non-small cell (NSCLC): adenocarcinoma (non-smokers), squamous (smokers), large cell, and non-squamous
small cell (SCLC): small cell (related to smoking)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Small cell lung cancer

A

clear relationship to smoking
paraneoplastic syndromes common
rapid cell growth fraction
highly sensitive to radiation and chemo
most common cancer to cause brain metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Non-small cell lung cancer

A

slower growth fraction
moderately sensitive to radiation
marginal sensitivity to chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Staging: SCLC

A

limited: tumor confined to hemithorax and contained in radiation port
extensive stage: tumor not confined to hemithorax of origin, not contained in radiation port, distant metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Small cell lung cancer highly sensitive to

A

radiation and chemo
chemo demonstrates 5-fold increase in median survival and is the mainstay of therapy
surgery is generally not a therapeutic option

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Limited stage disease

A

curative intent
combined modality: radiation + combo chemo - cisplatin + etoposide, radiation daily
maintenance chemo is of no value
prophylactic cranial radiation for pts obtaining a complete response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Regimens for limited stage

A

cisplatin + etoposide
carboplatin + etoposide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Extensive state

A

NO radiation!
rarely curable
platinum based combo chemo w/o radiation preferred: cisplatin or carbolatin based combo chemo - etoposide or irinotecan
chest radiation does not improve results
whole brain radiation therapy if brain metastases present
maintenance chemo is standard of care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Immunotherapy: extensive stage

A

first line: atezolizumab + carboplatin + etoposide; durvalumab + carboplatin + etoposide; durvalumab + cisplatin + etoposide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Complications of therapy for SCLC

A

most cisplatin-based regimens: serious chemo induced N/V, nephrotoxicity, ototoxicity, neuropathy
radiation therapy may cause fatigue, esophagitis, radiation pneumonitis, and cardiac toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

PD-1 inhibitors

A

pembrolizumab: option for metastatic SCLC in pts who have progressed on or after platinum-based chemo and at least 1 prior line of therapy
regardless of PD-1 status

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Non-small cell lung cancer

Study These Flashcards
A

moderately sensitive to radiation and low sensitivity to chemo
surgery is most efficacious!
radiation therapy may be given for early-stage NSCLC when surgery isn’t able to be performed

22
Q

Types of NSCLC

Study These Flashcards
A

resectable
unresectable
advanced/metastatic

23
Q

Treatment of resectable NSCLC

Study These Flashcards
A

neoadjuvant –> surgery –> chemo followed by immunotherapy or oral agent

24
Q

Neoadjuvant therapy NSCLC

Study These Flashcards
A

nivolumab + a platinum doublet in tumors >/= 4 cm or node +
adjuvant chemo now a standard of care; chemo decided on histology

25
Adjuvant therapy for non-squamous NSCLC
cisplatin + premetrexed
26
Adjuvant therapy for squamous NSCLC
cisplatin + gemcitabine cisplatin + docetaxel other recommended regimens: cisplatin + vinorelbine, cisplatin + etoposide if not able to tolerate cisplatin: carboplatin + pacitaxel or gemcitabine
27
Additional adjuvant therapies
alectinib: early stage and + for ALK mutations osimertinib: early stage, + for EGFR mutations (exon 19 deletion, exon 21 L858R) atezolizumab: early stage, high risk, PD-L1 >/=1% and no mutations pembrolizumab: early stage, high risk, and no mutations
28
Treatment of unresectable NSCLC
chemo and radiation NO surgery!
29
Unresectable disease: stage IIIB/IV
treatment is palliative, not curative concurrent chemoradiation: if non-squamous: carboplatin + premetrexed, cisplating + premetrexed, placlitaxel + carboplatin, cisplatin + etoposide if squamous: paclitaxel + carboplatin, cisplatin + etoposide if no disease progression after definitive concurrent chemoradiation: durvalumab or osimertinib
30
Stage III unresectable: immunotherapy
pembrolizumab - for pts who aren't candidates for surgery or definitive chemo with radiation PD-L1 >/= 1%
31
Unresectable stage III immunotherapy maintenance
durvalumab: for disease that has not progressed following concurrent chemo and radiation therapy max of 12 mo of therapy
32
Stage IIIB and IV disease
optimal regimen not defined: cisplatin/paclitaxel; cisplatin/gemcitabine; cisplatin/docetaxel; carboplatin/paclitaxel (fewer toxicities)
33
Advanced/metastatic NSCLC treatment
chemo + targeted therapy (1st line) chemo + targeted therapy (2nd line)
34
Metastatic NSCLC treatment considerations
adenocarcinoma --> target or no target squamous other check mutation status for all advanced/metastatic adenocarcinoma lung cancers
35
Tyrosine kinase inhibitors
if pt has targetable mutation and PD-L1 (+), it is preferred to use oral therapies 1st and then move to immunotherapy later
36
Metastatic NSCLC adenocarcinoma - EGFR targeting therapies
most common mutations: exon 19 deletion and exon 21 L858R mutation osimertinib - 1st line (T790 mutation) CYP3A4; rash, diarrhea, cardiomyopathy, QTc prolongation
37
Metastatic NSCLC adenocarcinoma - BRAF therapies
dabrafenib + trametinib 2 diff pathways; BRAF inhibitor SE --> skin cancer, use trametinib to take risk away dabrafenib: CYP3A4, fevers, secondary skin cancers trametinib: fevers, rash, visual changes, retinal detachment
38
Metastatic NSCLC adenocarcinoma - K-RAS G12C mutation
associated with cigarette smoking use as subsequent therapy after platinum-based chemo +/- immunotherapy sotorasib: N/V, diarrhea, increase in LFTs, rash, edema, decreased hemoglobin
39
Treatment - Metastatic disease - no mutation
if no mutation: check PD-L1 status - if PD-L1 positivity of >/= 1% will allow use of pembrolizumab therapy if PD-L1 negative: pembrolizumab or atezolizumab + chemo
40
Metastatic disease - first line: non-squamous
mutation negative NSCLC: carboplatin + pemetrexed + pembrolizumab
41
Treatment metastatic: squamous
if contraindication to immunotherapy: platinum doublet regardless of PD-L1 status if no contraindication to immunotherapy: pembrolizumab or pembrolizumab + chemo or atezolizumab
42
First line metastatic squamous
platinum based doublet carboplatin combined with gemcitabine or paclitaxel or nab-paclitaxel or docetaxel new standard with 3 drug regimen: pembrolizumab + carboplatin + paclitaxel or albumin bound paclitaxel
43
Next line of therapy for metastatic squamous
tyrosine kinase inhibitor (if positive) immunotherapy or non-platinum chemo agents: nivolumab, atezolizumab, or pembrolizumab other single agents: pemetrexed, paclitaxel, docetaxel, gemcitabine, vinorelbine
44
Immunotherapy toxicities
safety: rare and serious immune mediated toxicities: pneumonitis, colitis, hepatitis, nephritis, endocrine - thyroid, pituitary
45
Lab values to monitor in pts receiving immunotherapy
amylase, lipase, TSH, free T4, CBC with differential, complete metabolic panel
46
Lung cancer screening
sputum cytology, serial chest X-rays of no proven benefit low dose CT scans decreased mortality by 20% - lots of false positives can consider screening in pts considered to be high-risk
47
Lung cancer prevention trials
CARET trial: 28% increase of lung cancer with beta carotene smoking cessation decreased risk of 2nd cancers
48
What would be the preferred treatment regimen for someone with limited stage SCLC?
radiation + combination chemo: cisplatin + etoposide, radiation daily no maintenance therapy
49
What would be the preferred treatment regimen for someone with extensive stage SCLC?
atezolizumab + carboplatin + etoposide chemo followed by maintenance atezolizumab OR durvalumab + carboplatin + etoposide chemo followed by durvalumab maintenance therapy
50
What would be the preferred regimen for someone with stage II, NSCLC with no mutations?
stage II = resectable surgery, adjuvant therapies

PHRM 864 (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions